313 related articles for article (PubMed ID: 34230008)
41. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
[TBL] [Abstract][Full Text] [Related]
42. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
43. Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.
Gaudreau PO; Lee JJ; Heymach JV; Gibbons DL
Clin Lung Cancer; 2020 Jul; 21(4):384-388. PubMed ID: 32299768
[TBL] [Abstract][Full Text] [Related]
44. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
45. Tumor loss-of-function mutations in STK11/LKB1 induce cachexia.
Iyengar P; Gandhi AY; Granados J; Guo T; Gupta A; Yu J; Llano EM; Zhang F; Gao A; Kandathil A; Williams D; Gao B; Girard L; Malladi VS; Shelton JM; Evers BM; Hannan R; Ahn C; Minna JD; Infante RE
JCI Insight; 2023 Apr; 8(8):. PubMed ID: 37092555
[TBL] [Abstract][Full Text] [Related]
46. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
47. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
48. Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers.
Donnelly LL; Hogan TC; Lenahan SM; Nandagopal G; Eaton JG; Lebeau MA; McCann CL; Sarausky HM; Hampel KJ; Armstrong JD; Cameron MP; Sidiropoulos N; Deming P; Seward DJ
Carcinogenesis; 2021 Dec; 42(12):1428-1438. PubMed ID: 34849607
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
[TBL] [Abstract][Full Text] [Related]
50.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract][Full Text] [Related]
51. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
Caetano MS; Zhang H; Cumpian AM; Gong L; Unver N; Ostrin EJ; Daliri S; Chang SH; Ochoa CE; Hanash S; Behrens C; Wistuba II; Sternberg C; Kadara H; Ferreira CG; Watowich SS; Moghaddam SJ
Cancer Res; 2016 Jun; 76(11):3189-99. PubMed ID: 27197187
[TBL] [Abstract][Full Text] [Related]
52. Circular RNA
Chen X; Mao R; Su W; Yang X; Geng Q; Guo C; Wang Z; Wang J; Kresty LA; Beer DG; Chang AC; Chen G
Autophagy; 2020 Apr; 16(4):659-671. PubMed ID: 31232177
[TBL] [Abstract][Full Text] [Related]
53. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
54. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
[TBL] [Abstract][Full Text] [Related]
55. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Luo F; Luo M; Rong QX; Zhang H; Chen Z; Wang F; Zhao HY; Fu LW
J Immunother Cancer; 2019 Sep; 7(1):245. PubMed ID: 31511071
[TBL] [Abstract][Full Text] [Related]
56. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Passiglia F; Bironzo P; Righi L; Listì A; Arizio F; Novello S; Volante M; Scagliotti GV
Clin Lung Cancer; 2021 Jan; 22(1):e63-e66. PubMed ID: 32917522
[TBL] [Abstract][Full Text] [Related]
57. A STING operation to expose KRAS and STK11 co-mutated lung cancers.
Skoulidis F; Heymach JV; Cascone T
Cancer Cell; 2022 Oct; 40(10):1073-1076. PubMed ID: 36220070
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
Li R; Salehi-Rad R; Crosson W; Momcilovic M; Lim RJ; Ong SL; Huang ZL; Zhang T; Abascal J; Dumitras C; Jing Z; Park SJ; Krysan K; Shackelford DB; Tran LM; Liu B; Dubinett SM
Cancer Res; 2021 Jun; 81(12):3295-3308. PubMed ID: 33853830
[TBL] [Abstract][Full Text] [Related]
59. Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma.
Cheng L; Creasy T; Pilataxi F; Greenlees L; Vence L; Sridhar S; Streicher K
Cancer Immunol Immunother; 2022 May; 71(5):1167-1181. PubMed ID: 34623465
[TBL] [Abstract][Full Text] [Related]
60. Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of
Padda SK; Aredo JV; Vali S; Singh NK; Vasista SM; Kumar A; Neal JW; Abbasi T; Wakelee HA
JCO Precis Oncol; 2021 Nov; 5():153-162. PubMed ID: 34994595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
